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P293 – Table 1. Rheological properties of hylan G-F 20 and NASHA
Product Name HA Conc. Elastic Modulus @ 5 Hz Rupture Stress @ 1 Hz Phase Angle @ 5Hz Viscosity @ 1 s-1
(mg/ml) (Pa) (Pa) (degree) (Pa s)
hylan G-F 20 9 100 -140 25 - 40 7 - 9 45 - 60
NASHA 20 400 -1200 4 - 9 13 - 15 30 - 45
Fig. 1. Dilution durability of hylan G-F 20 and NASHA.
gested that NASHA contains hard gel particles with very weak
force between the gel particles. NASHA acts as a two phase
system resulting in a suspension of hard particles in buffer.
This was confirmed from the dilution durability measurement. As
shown in Figure 1, NASHA has very low dilution durability (25%)
compared to hylan G-F 20 (110%). This suggests that NASHA’s
viscoelastic properties degraded at a low level of dilution. In
contrast, hylan G-F 20 behaves like soft particles suspended in
a long-chain viscoelastic polymer solution, and has much bet-
ter tolerance against dilution. In the muscle implantation study,
the two products showed similar tissue reactivity compared to
HDPE at 7 days post implantation. By four weeks, hylan G-F
20 had little or no material remaining at the implantation site
and had a reactivity score similar to the HDPE control. However,
the NASHA had a higher reactivity score than the HDPE control
(NASHA 9.4 vs HDPE 2.3) and is distinctly visible at the implant
site in photomicrographs (Figure 2).
Fig. 2. Photomicrograph of NASHA following 4 weeks of implantation in rabbit
muscle.
Conclusions: From our studies, we conclude that hylan G-F 20 is
a much softer and smoother gel, has better dilution tolerance, and
has less tissue reactivity than NASHA. As a viscosupplement,
hylan G-F 20 is expected to provide better lubrication, shock
absorption (under moderate dilution) and cartilage protection
than NASHA.
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Purpose: To study the effect of avian chondroitin sulfate (CS)
on both the synthesis rate and the molecular size of hyaluronan
(HA) produced by human OA synoviocytes and chondrocytes,
cultured in the presence or absence of interleukin-1β (IL-1β).
To determine in parallel the expression of key-enzymes of HA
synthesis and the CS-induced signaling pathways.
Methods: Synovial cells and articular chondrocytes were ob-
tained from OA patients undergoing hip arthroplasty, and cul-
tured in 10% FCS-containing DMEM with CS (1-100 μg/ml).
The medium was changed every 2 days. After 4 days, culture
medium was replaced with serum free DMEM containing 1%
ITS, with or without IL-1β (1 ng/ml) and then, the incubation
was further continued for 24 or 48 h. At the end of experi-
ments, culture medium was harvested for HA assay, using an
ELISA-like method. Aliquot samples from medium and cell layer
were also collected for HPLC size-exclusion analysis of the HA
produced. RNA was isolated and reverse transcribed to cDNA,
which was then subjected to relative quantitative real-time PCR
(Q-RT-PCR) procedure, using the ABI PRISM 7000 and SYBR
green detection and specific primers for hyaluronan synthases
(HAS) 1, 2 and 3 and UDP-glucose dehydrogenase (UGDH).
RT-PCR data were normalized with GAPDH mRNA and gene
expression relative to control was calculated with the delta delta
cycle to threshold (ddCt) method. Cytoplasmic protein extracts
were prepared and used in Western-blot analysis of ERK1/2.
Results: CS treatment caused a significant increase of HA
production in both synoviocytes and articular chondrocytes. The
effect was dose and time dependent and was observed for
control and IL-1β-treated cultures. In parallel, the mRNA steady-
state levels of the hyaluronan synthases HAS1 and HAS2 were
found to be elevated by CS. Similarly, CS stimulated basal and
IL-1β induced mRNA expression of UGDH in both synoviocytes
and chondrocytes. On the other hand, the expression of HAS3,
which is known to be rather responsible for low-molecular HA
synthesis, was down-regulated by CS in both controls and IL-1β-
treated cultures. Interestingly, the HPLC profile of HA produced in
the presence of CS revealed a greater amount of high molecular
size HA, compared to controls. Furthermore, when combined
with IL-1β, CS caused a reduction of the low molecular weight
HA fractions induced by the cytokine. The signaling pathways
elicited by CS in synoviocytes and chondrocytes are unknown.
Here, we demonstrated that the MAP kinases ERK1/ERK2 were
activated upon CS treatment, suggesting that this pathway could
be implicated in the CS modulation of HA synthesis by joint cells.
Conclusions: CS enhances HA production by articular cells,
with production of high molecular forms of the glycosamino-
glycan, through concomitant increase of UGDH, HAS1, HAS2
and decreased HAS3 expression. The effect is associated with
phosphorylation of ERK1/2 kinases, suggesting a role of this sig-
naling pathway in the mechanism underlying CS action. These
data support the hypothesis that CS, which is clinically used to
improve OA symptoms, can exert a beneficial effect through in-
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creased release of high molecular weight HA in the synovial fluid
and enhanced aggregating potential for cartilage proteoglycans.
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Purpose: To determine whether Tai Chi or hydrotherapy classes
for people with chronic symptomatic hip or knee osteoarthritis
(OA) can result in measurable clinical benefits.
Methods: A randomised controlled trial was conducted among
152 people, aged 59 years and over, with chronic symptomatic
hip or knee OA. Participants were randomly allocated for 12
weeks to hydrotherapy classes (n=55), Tai Chi classes (n=56) or
waiting list control (n=41). Outcomes were assessed at 12 weeks
(post treatment) and 24 weeks (sustainability) after randomisa-
tion and included pain and physical function (WOMAC), general
health status (SF-12v2), psychological well being and physical
performance (‘up and go’, 50 ft walk time, timed stair climb).
Results: At the 12 week post treatment assessment, 49%
(n=27), 34% (n=19) and 15% (n=6) of participants allocated
to hydrotherapy, Tai Chi and control group, respectively, were
treatment responders according to OMERACT-OARSI responder
criteria D. The difference in treatment responder rate between
the three allocation groups was significant (chi-squared=12.4, df
= 2, p=0.002). Compared with control, participants allocated to
hydrotherapy classes demonstrated mean improvements (95%
confidence interval) of 6.5 (0.4 to 12.7) and 10.5 (3.6 to 14.5)
for pain and physical function scores (range 0-100), respectively,
while participants allocated to Tai Chi classes demonstrated im-
provements of 5.2 (-0.8 to 11.1) and 9.7 (2.8 to 16.7). The 95%
CI for treatment effect sizes for physical function for hydrotherapy
or Tai Chi classes ranged from moderate to large (.50 to .76).
Both class allocations achieved significant improvements in the
SF-12 physical component summary score, but only allocation to
hydrotherapy classes achieved significant improvements in the
measures of physical performance. All significant improvements
were sustained at 24 weeks after randomisation. In this almost
exclusively Caucasian sample, class attendance was higher for
hydrotherapy with 81% attending at least half of the available 24
classes, compared with 61% for Tai Chi.
Conclusions: Access to either hydrotherapy or Tai Chi classes
can provide sustained improvements in pain and physical func-
tion for many older, sedentary people with chronic symptomatic
hip or knee OA. The improvements achieved in physical function
were greater than those demonstrated for traditional land-based
exercise programs.
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Purpose: To compare the clinical effectiveness, functional out-
come and patient satisfaction following intra articular injection
with Synvisc® and Hyalgan® in patients with osteoarthritis (OA)
of the knee
Methods: 356 consecutive patients with OA of the knee were
randomized into two groups to receive Hylan G-F-20 -Synvisc
(n=184) or Sodium Hyaluronate -Hyalgan (n=172). Weight bear-
ing radiographs were reviewed at baseline to grade the degree
of OA using the Kellgren-Lawrence system. All patients were
prospectively reviewed by blinded independent assessors at pre
injection, 6 weeks, 3, 6, 12 months. Knee pain and patient sat-
isfaction was measured on a VAS (0-10, 10 as worst pain).
Functional outcome was assessed using WOMAC, UCLA, Teg-
ner, Oxford knee score and EuroQol- 5D scores. Mean follow up
was 12 months
Results: The mean age of the randomised patients was 66.7 yrs.
Patients in both groups predominantly had grade III OA (Synvisc-
61% and Hyalgan-59%). There were no significant differences in
the age, sex and degree of OA between the two groups. Knee
pain on VAS improved from 6.7 to 3.2 by 6 weeks (p=0.02) and
was sustained until 12 months (3.7, p=0.04) with Synvisc. In
the Hyalgan group, pain improved from 6.6 to 5.7 at 6 weeks
(p>0.05) and to 4.1 at 3 months (p=0.04) but was sustained only
until 6 months (5.9, p>0.05). Improvements in the WOMAC pain
and physical activity subscales were significantly superior in the
Synvisc group at 3 months (p=0.02), 6 months (p=0.01) and 12
months (p=0.02). Similarly, the Tegner, UCLA and Oxford knee
scores were significantly better in the Synvisc group at 6 weeks
(p=0.02) and 6 months (p=0.03) and 12 months (p=0.04) post
injection whilst there was no difference between the groups at 3
months. There was no significant difference in the EQ-5D scores
at 6 weeks, and 3 months between the two groups. The EQ-5D
description scores were higher in the Synvisc group at 6 months
(p=0.03) and 1 year (p=0.04). General patient satisfaction was
better in the Synvisc group at all times although statistically
significant at 3 months (p=0.01) and 6 months (p=0.02). There
was local increase in knee pain in one patient who received
Synvisc, which settled by 4 weeks. Patient compliance was
99.2% in the Synvisc group as compared to 92.2% in the Hyalgan
group due to the number of recommended injections. There was
no difference in the cost of the drugs, but the total treatment cost
was 23% more in the Hyalgan group due to the two additional
visits to complete the course of treatment
Conclusions: Although both treatments offered significant pain
reduction, it was achieved earlier and sustained for a longer pe-
riod in patients with Synvisc. Patients treated with Synvisc have
demonstrated an early increase in activity levels as evidenced
by the WOMAC, UCLA and Tegner scores. Both treatments were
well tolerated, however, a local reaction of pseudo sepsis was ob-
served with Synvisc in one patient. The total treatment cost, both
for the patient and the hospital are higher with Hyalgan. From
this study, it appears that the clinical effectiveness and general
patient satisfaction are better amongst patients who received
Synvisc
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Purpose: Recently, attention has been attracted that oxidative
stress and its related chondrocyte aging have an important role
